Skip to main content

Additional Advances in Soft Tissue Sarcoma With Brian Rubin, MD, PhD

Oncology Data Advisor® · Additional Advances in Soft Tissue Sarcoma With Brian Rubin, MD, PhD Last year, Brian Rubin, MD, PhD, Chair of Pathology and Laboratory Medicine and the Chief of Diagnostics at the Cleveland Clinic, served as co-chair for i3 Health's continuing medical education (CME)–/nursing continuing professional development (NCPD)–approved virtual tumor board: Multidisciplinary Management of Advanced Soft Tissue Sarcoma, alongside Kathleen Polson, Nurse Practitioner at Da...

Continue reading

Additional Advances in Soft Tissue Sarcoma With Brian Rubin, MD, PhD

Last year, Brian Rubin, MD, PhD, Chair of Pathology and Laboratory Medicine and the Chief of Diagnostics at the Cleveland Clinic, served as co-chair for i3 Health's continuing medical education (CME)–/nursing continuing professional development (NCPD)–approved virtual tumor board: Multidisciplinary Management of Advanced Soft Tissue Sarcoma, alongside Kathleen Polson, Nurse Practitioner at Dana-Farber Cancer Institute, and Shreyaskumar R. Patel, MD, Center Medical Director of the Sarcoma Center ...

Continue reading

Optimizing Proficiency for Treating Advanced Soft Tissue Sarcoma

An educational enduring online activity provided by i3 Health has demonstrated knowledge gains regarding the best treatment and management of advanced soft tissue sarcoma. Soft tissue sarcomas are a heterogeneous group of malignancies that arise primarily from the mesodermal tissues of the extremities, trunk and retroperitoneum, and head and neck. The American Cancer Society estimated that 13,190 new cases will be diagnosed in the United States in 2022, and 5,130 of these cases are estimated to ...

Continue reading

Understanding Soft Tissue Sarcoma: Vicki L. Keedy, MD, MSCI, and Brian P. Rubin, MD, PhD

Soft tissue sarcoma is a rare cancer, estimated to be 0.7% of all new cancer cases in 2021. In this excerpt of the transcript from their continuing medical education/nursing continuing professional development (CME/NCPD)-approved activity, Virtual Tumor Board: Optimizing Personalized Care Plans for Patients with Advanced Soft Tissue Sarcoma, Vicki L. Keedy, MD, MSCI, of the Vanderbilt-Ingram Cancer Center, and Brian P. Rubin, MD, PhD, of the Cleveland Clinic, discuss the rarity of...

Continue reading

Soft Tissue Sarcoma In Young Versus Older Adulthood

Soft tissue sarcoma, a rare cancer in tissues that connect, support, and surround body structures, is found in various age groups and typically has a five-year survival rate of 65%. When investigators conducted research comparing the clinical presentation, histological subtype, treatment, and outcome of soft tissue sarcoma in adolescents and young adults versus older adults, they found several differences between the two populations that could aid in future research on this disease. For this stu...

Continue reading

Tazemetostat Approved for Epithelioid Sarcoma

The FDA has granted accelerated approval to tazemetostat (TazverikTM, Epizyme) for the treatment of adult and pediatric patients aged 16 or older with unresectable locally advanced or metastatic epithelioid sarcoma. Epithelioid sarcoma, which often occurs in young adults and comprises less than 1% of all soft tissue sarcomas, carries a high risk of local and regional spread, and it metastasizes in approximately 30% to 50% of cases. Tazemetostat, a first-in-class selective enhancer of zeste ...

Continue reading